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Indocyanine Green Elimination Test in Orthotopic 
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Objective. To determine its predictive capability on 
graft quality and resultant clinical outcome, the indocy-
anine green (ICG) elimination test was performed by a 
spectrophotometric method and a noninvasive finger-
piece method with 50 orthotopic liver transplantations. 
Background. Early detection of poor-functioning he· 
patic grafts is one of the most important issues in liver 
transplantation, but no reliable methods exist. Methods. 
The ICG test was performed after 50 orthotopic liver 
transplantations on postoperative days 1,3, and 7. Indo-
cyanine green elimination constants (KICG ) were mea-
sured by both a standard spectrophotometric analysis 
(KICG-B) and by a finger-piece method (KICG-F). The pa-
tients were followed for a minimum of 3 months after 
transplantation. Results of ICG tests were correlated 
with various clinical determinations. Results. Twelve of 
the 50 grafts were lost within three months, of which 7 
were related to graft failure. Multivariate analysis using 
the Cox proportional hazard model revealed that KICG 
on postoperative day 1 was a better predictor of liver-
related graft outcome than any of the conventional liver 
function tests. Furthermore, KICG values showed signifi-
cant correlation with the severity of preservation iujury, 
longer intensive care unit (ICU) and hospital stay, pro-
longed liver dysfunction, and septic complications. Cor-
relation of KICG values by the spectrophotometric 
method with those by the finger-piece method was 
highly satisfactory in the grafts that had KICG-B <0.15 
min 1 (y = O.868x -0.011, r = .955). Conclusion. The ICG 
elimination test, conducted spectrophotometrically or 
optically on the day after liver transplantation, is a reli-
able indicator of graft quality and subsequent graft out-
come early after liver transplantation. (HEPATOLOGY 
1996;24:1165-1171.) 
Despite significant improvements in patient outcome after 
orthotopic liver transplantation, primary nonfunctioning 
and/or poor functioning grafts in the immediate postoperative 
period remain an important problem. l,2 A reliable method to 
evaluate graft viability and to predict graft outcome in the 
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perioperative period is needed; however, conventional liver 
function tests have limited reliability3,4 and the results of 
various quantitative liver function tests have been conflict-
ing.5-lo 
Recently, the indocyanine green (leG) eli,nination test has 
been suggested as a predictor of graft viability and outcome, 
but its significance has not been fully clarified.5.7.lu2 The 
primary goal of this study was to determine whether the leG 
elimination test can predict graft viability and outcome in 
the early postoperative period, The secondary g~al of this 
study was to evaluate the applicability of a new noninvasive 
optical finger-piece method13 against the conventional spec-
trophotometric method for leG determination. 
MATERIALS AND METHODS 
Case Material 
From May 1, 1994 to October 31, 1994, 126 orthotopic liver trans-
plantations were performed in 120 adult patients at Presbyterian 
University Hospital, Pittsburgh, PA. Of these, 50 liver trans-
plantations in 47 patients were randomly chosen for this study. 
There were 26 male and 21 female patients with a median age of 53 
years, ranging from 31 to 73 years, Of 43 patients who received 
a primary graft, 3 underwent liver retransplantation in the early 
posttransplantation period because of problems with the graft. The 
remaining 4 patients entered the study with replacement of a graft 
that had been transplanted previously. 
Operative Procedure 
Cadaveric liver grafts were harvested by a flexible multiple organ 
procurement technique described elsewhere.!4 Median cold ischemia 
time of the liver was 12.1 hours, ranging from 7.6 to 25.0 hours. 
Recipient hepatectomy and liver replacement were performed by the 
standard technique in 30 cases and by the piggyback method in 20 
cases. 15 Median warm ischemia time of the graft was 50 minutes 
ranging from 28 to 68 minutes. ' 
Postoperative Management 
Postoperative immunosuppression was with tacrolimus and ste-
roids. The rationale for dose adjustment of these agents and supple-
mentary administration of steroids, azathioprine, or OKT3 have been 
described elsewhere.2 
Causes of graft malfunction were investigated by pathological, 
radiological, and microbiological studies. 1 Graft rejection was diag-
nosed from clinical findings followed by histopatbology of needle liver 
biopsies. Vascular complications were examined by DOPlller ultraso-
nography, followed by abdominal angiography when inaicated. Per-
cutaneous transhepatic cholangiography or T-tube cholangiography 
was performed in cases with possible biliary problems. Whenever 
infectious complications were suspected, the blood, sputum. urine, 
peritoneal fluid, and abdominal wound discharge were cultured to 
identify causative microorganisms. 
ICG Study 
Indocyanine green elimination tests were simultaneously per-
formed by the standard spectrophotometric method and with the 
optical finger-piece method. The study was performed with the ap-
proval of the Institutional Review Board. Consent forms were ob-
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tained from all of the study participants. The results of the ICG 
tests were blinded to the attending physicians who manage liver 
reci pients. 
Standard Method. On the mornings of postoperative days 1,3, and 
7, ICG (Cardio-green, Hynson, Westcott & Denning, Baltimore, MD) 
at a dose of 0.5 mg/kg was given as an intravenous bolus through a 
peripheral vein. Two milliliters of blood was collected via an arterial 
or central venous line 5, 7, 10, and 15 minutes after ICG injection. 
After two-fold dilution of the plasma with saline, ICG absorbance 
was measured using a UVNIS spectrophotometer (Lambda 1, Per-
kin-Elmer, Norwalk, CT) at 805 nm and 900 nm. The correction for 
blank density of the plasma was performed by the method of Niel-
sen. Hi The ICG plasma elimination data were fitted to a monoexpo-
nential equation using a log-linear least square method. Indocyanine 
green elimination rate constant (Kwc-B), which represented the slope 
ofthe exponential equation, was used as a representative parameter 
ofICG elimination. 
Optical Finger·Piece Method. An ICG clearance meter (RK-lOOO, 
Sumitomo Electric, Osaka, Japan) was used to optically measure 
ICG elimination. A finger-piece optical sensor was adopted onto the 
tip of the index finger of the arm not being used for ICG injection, 
and the lead wires were connected to a microcomputer. The optical 
sensor was composed of a pair of light-emitting diodes and a photo 
diode, by which faint changes in ICG concentration in the fingertip 
could be monitored as changes in sensor signal voltage per second. 
The ICG elimination rate constant (K1CG-F) was calculated automati-
cally using the 600 data obtained between 5 minutes and 15 minutes 
after ICG injection. 13 
Clinical Determinations 
The clinical course of all recipients was followed for a minimum of 
3 months after transplantation. Information on the donor, operative 
procedure, postoperative graft function, and graft outcome were pro-
spectively collected for each transplantation. Routine liver function 
tests, including aspartate aminotransferase (AST), alanine amino-
transferase (ALT), prothrombin time (PT), and total bilirubin, were 
serially followed. Information on intensive care unit (ICU) and hospi-
tal stay, cause of graft loss and patient death, histological severity 
of graft rejection and preservation injury, and the occurrence of sep-
sis were also recorded. Graft losses were classified into two groups: 
those resulting from graft failure with final total bilirubin greater 
than 10 mg/dL, and others caused by technical failure or extrahepatic 
reasons. Prolonged postoperative liver dysfunction was defined by 
total bilirubin greater than 5 mg/dL at postoperative day 14. The 
severity of graft rejection and preservation injury was evaluated by 
a single pathologist and subjectively graded as none, mild, moderate, 
and severe. Finally, sepsis was diagnosed according to the Critical 
Care Medicine Consensus Conference. 17 
Statistics 
Continuous data were presented as median and ranges, and com-
parisons between groups were performed using the Mann-Whitney 
U test or the Kruskal-Wallis test. Categorical data are presented 
as a percentage, and the difference was evaluated by the X2 test. 
Correlation was tested by means of linear regression analysis. To 
determine independent variables that were significantly related to 
the elected end-points, univariate analysis was performed to enter 
the Cox proportional hazard model for stepwise logistic regression 
analysis, followed by forward stepwise multivariate analysis using 
the univariate significant variables. These statistical analyses were 
performed using the statistical software packages Statistica (Stat-
Soft, Tulsa, OK) and SPSS (SPSS Inc., Chicago, IL). 
RESULTS 
Graft Outcome. After a 3-month follow-up, 38 (35 primary 
grafts and 3 of the retransplanted grafts) of 50 grafts were 
functioning (group I). Three-month graft survival was 76% 
(38/50), and patient survival was 81% (38/47). Twelve grafts 
were lost to retransplantation or patient death, of which 
seven were related to graft failure (group IIA), and 5 were 
caused by technical or extrahepatic reasons (group lIB). Ta-
-------------_.- ----
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ble 1 summarizes the causes of the 12 graft losses. Of the 
parameters studied with the donor, recipient, and operative 
procedure, only old donor age was significantly related to 
poor graft outcome. The median age and range of the liver 
donors in group I was: 39 (11 to 63) years old; group 1IA: 59 
(31 to 69) years old; and group lIB: 32 (6 to 43) years old. 
Group IIA was significantly disadvantaged (P = .0089). 
Other Clinical Results. Median duration of ICU stay was 
11 days. Twenty patients (40%) stayed in the ICU longer 
than 7 days, and 10 more patients (20%) died while in the 
ICU. Mean hospitalization was 44 days. Sixteen patients 
(32%) required hospitalization for more than 30 days, and 13 
other patients (26%) could not be discharged from the hospi-
tal. Total bilirubin decreased to <5 mgldL within 14 days in 
35 grafts (70%), but 15 grafts (30%) showed prolonged graft 
dysfunction or graft failure. By histological study of liver bi-
opsy specimens or removed grafts, 35 grafts (70%) had preser-
vation injury, with moderate to severe grade in 20 (40%). 
Histological evidence of graft rejection was diagnosed in 22 
grafts (44%), of which 6 were graded moderate to severe. 
Twelve grafts E:~4%F developed septic complications caused 
by bacteria (n = 9) or fungi (n = 3). 
ICG Elimination Test. A total of 146 ICG injections were 
performed in this study. None of the patients developed hypo-
tension, dyspnea, headache, or rash, abrupt worsening of 
graft function, or any other side effects. When the 50 ICG-
studied grafts were compared with 67 grafts that received no 
ICG tests during the study period, there were no statistical 
differences in graft and patient survival and postoperative 
changes in routine liver function tests. 
Figure 1 illustrates the correlation of indocyanine green 
elimination constant (KICG ) values determined by the KICG-B 
method and the KrCG-F method. Irrespective of postoperative 
days on which the ICG tests were performed, both measure-
ments showed highly significant correlation (y = 0.861x 
-0.009, r = .886, n = 146). If K,cG-B was >0.15 min-1 and 
KrcG-F was >0.1:2 min-\ the correlation between the two was 
rather scattered (y = 0.533x + 0.055, r = .323, n = 68), 
because KrCG-F values fluctuated at this or higher levels. At 
lower levels, however, both KrcG-B and KrcG-F had an almost 
linear correlation (y = 0.868x - 0.011, r = .955, n = 78). 
KICa and Clinical Outcome. Postoperative changes in KICG 
of individual patients from the three groups are shown in 
Fig. 2, where KlCG levels are arbitrarily divided into three 
classes: class A (KrCG-B > 0.10 minI); class B (0.10 min-I> 
KrcG-B > 0.06 min-I); and class C (KrcG-B < 0.06 min-I). 
Using the equation determined with lower KICG-B values, 
Krcc;-B at 0.10 min- I and 0.06 min- I corresponded to KrcG-F 
at 0.075 min- 1 and 0.04 min-I, respectively. On postoperative 
day (POD) 1, 32 of the 38 group I patients (84%) had KrcG in 
class A, whereas all of the group IIA patients were either 
class B (317) or dass C (417). Graft failure occurred in 0% (01 
36) of class A, 30% (3110) of class B, and 100% (4/4) of class 
C when classified by KrcG on POD 1. After POD 1, KrcG of 
most group I patients remained high, but that of group IIA 
and group IIB showed further reductions. Of the 20 grafts 
that showed moderate to severe preservation injury on needle 
biopsy or removed graft, one patient died of primary nonfunc-
tion at POD 2, and 17 grafts had KrcG at class B or class C 
on POD 3. The incidence of moderate to severe preservation 
injury was 7.1% (2/28) of class A, 66.7% (8112) of class B, and 
100% (9/9) of class C by KrcG on POD 3 (Fig. 3A). Similarly, 
the incidence of Eepsis was 3.6% (1128) of class A, 80% (8/10) 
of class B, and 75% (3/4) of class C by KICG on POD 7 (Fig. 
3B). 
KICa and Liver .Function Tests. Correlation of KrcG-B levels 
with those of AST, ALT, PT, and total bilirubin on POD 1 is 
shown in Fig. 4. Although both AST (y = -7759x + 3238, r2 
= .02, not significant) and ALT (y = -675x + 975, r2 = .00, 
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TABLE 1. Causes of Graft Loss and Mortality in 12 Group-II Patients 
Graft Klcn-B (min- J ) KICG-F (min-I) 
Patient Survival 
# Days POD 1 POD 3 POD 7 POD 1 POD 3 POD 7 Re-OLTX Patient Outcome (d), Cause of Death 
Group IIA 
1 3 2 .047 .026 No Died (2), PNF 
2 13 20 .058 .048 .044 .031 .029 .026 No Died (20), sepsis 
3 16 25 .045 .014 .015 .028 .003 .000 No Died (25), sepsis 
4 31 40 .087 .078 .062 .061 .069 .048 No Died (40), sepsis 
5 32 5 .034 .012 .018 .003 Yes Alive after Rc-OLTX for PNF 
6 36 5 .079 .021 .053 .006 Yes Alive aftc'r Re-OLTX for PNF 
7 50 73 .081 .07 .054 .063 .051 .038 No Died (73), sepsis 
Group IIB 
Died (74), CNS, withdrawal of 
8 74 .156 .107 .093 .093 .058 .061 No support 
Died (39), TTP, withdrawal of 
2 25 39 .178 .141 .069 .178 .115 .050 No support 
3 27 74 .107 .081 .061 .053 .063 .040 Yes Died (92), sepsis 
4 35 18 .123 .231 .184 .094 .202 .157 Yes Alive after Re-OLTX for HAT 
5 49 64 .07 .036 .081 .046 .021 .059 No Died (64), pulmonary bleeding 
Abbreviations: Re-OLTX, retransplantation of the liver; PNF, primary nonfunction (graft loss within 2 weeks after transplantation); CNS, central nervous 
system dysfunction; TTP, thrombotic thrombocytopenic purpura; HAT, hepatic artery thrombosis. 
not significant) were not correlated, PT (y = -27.3x + 21.1, 
r2 = .18, P < .005) and total bilirubin (y = -66.1x + 18.1, r2 
= .36, P < .001) values had an inverse relationship with 
K,cG-B. However, in contrast to KICG-B, higher PT and total 
bilirubin on POD 1 did not always reflect poor outcome of 
transplanted grafts. 
Correlation of KICa and Liver Function Tests With Clinical 
Outcome. Correlation of various clinical outcomes with the 
results of the ICG elimination test and routine liver function 
tests was examined (Table 2). Using a univariate analysis, 
KICG values determined both spectrophotometrically and opti-
cally showed significant correlation with all determinants 
except for nonliver-related graft loss and rejection. Of the 
routine liver function tests, total bilirubin level and highest 
PT within 7 postoperative days reflected the incidence of 
overall and liver-related graft loss. The highest levels of ALT, 
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FIG. 1. Relationship between KICG-B and KICG-F. Data represent all 146 
ICG elimination tests. See text for linear regression. 
AST, PT, and total bilirubin correlated with preservation in-
jury. When multivariate analysis was applied, K,cG-B at POD 
1 was the best indicator for overall and liver-related graft 
loss, and K,cG-F at POD 7 reflected prolonged hospitalization. 
The incidence ofliver-unrelated graft loss and graft rejection 
was unpredictable using any of these parameters. 
DISCUSSION 
Causes of primary non function and dysfunction in hepatic 
allografts after orthotopic transplantation are multifactorial. 
The risk factors include age, gender, and medical condition 
of the donor, cause and severity of the recipient's liver dis-
ease, cold ischemia time and warm ischemia time of the graft, 
difficulty and amount of blood transfused during surgery, 
and blood type and immunological compatibility between the 
donor and the recipient. Whatever the causes, 5% of the 
grafts require urgent retransplantation, and 15% of the 
grafts need prolonged management for survival, because of 
poor initial graft function. 1-4 A reliable method enabling early 
determination of such grafts is crucial. 
Clinically, malfunction of hepatic allografts is predicted if 
the recipients remain unconscious, hypotensive, and oliguric 
or anuric after transplantation. The grafts make small 
amounts of pale bile. Laboratory findings, including acidosis, 
hypoglycemia, PT prolongation, elevated liver enzymes, and 
high bilirubin level, are supportive of the diagnosis of irre-
versible graft damage, but are not always conclusive. With 
0.3 0.3 Group liB 0.3 Group I Group IIA 
0.' 0.' 
" i 
'1' 
0 
!.i 
0.1 0.1 
0.06 
Days after transplantation Days after tnnsplantation Days.rter transplantation 
FIG. 2. Changes in KrcG-B levels of liver recipients with a functioning graft 
(group 1) or graft loss from either graft failure (group HA) or liver-unrelated 
reasons (group IIB). 
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the aid of clinical chemical, histological and radiological stud-
ies, the decision to regraft is made mostly from the experience 
of the liver transplantation surgeons. l 
A few quantitative functional tests have been proposed for 
determining posttransplant graft quality. However, each has 
limitations per se in terms of sensitivity, specificity, and prac-
ticality. For instance, biochemical recovery of hepatocyte en-
ergy metabolisml8 and serum amino acids profile10 after liver 
transplantation correlates with the quality of the graft, but 
the determination is too complex and takes too long to apply 
clinically. Some investigators5.8 have reported that measure-
ment of monoethylglycin-exylidide (MEGX) formation after 
intravenous lidocaine administration is a good predictor of 
graft function. However, because lidocaine is metabolized by 
the drug-metabolizing enzyme P_450,20 the rate of formation 
could be influenced by the medications routinely used after 
liver transplantation such as immunosuppressants, steroids, 
antibiotics, and calcium ion channel blockers. The rate of 
MEGX formation can also be affected by extrahepatic lido-
caine metabolism.21 In this study, MEGX was determined by 
a high-pressure liquid chromatography method simulta-
neously with the ICG elimination test (Fig. 5). Although the 
correlation between KICG-Band MEGX was highly significant 
(y = 276x + 13, r2 = .28, P < .001), a low MEGX value did 
not predict poor graft outcome when compared with low KICG-
B. Arterial ketone body ratio, which reflects the redox state 
of hepatocytes, has limitations for routine clinical use be-
cause of the need for glucose loading before measurements, 
and of the exclusion of diabetic patients. lo A recent report 
has indicated that AKBR may be influenced by extrahepatic 
metabolism of the ketone bodies. 2 :! 
The present investigation was conducted to study whether 
the ICG elimination test can safely be used as a predictor of 
graft quality after liver transplantation in patients. The re-
sults suggest that low KICG levels «0.06 min 1 using KIeG-
Band <0.04 min- l using KICl;-F), especially on POD 1 after 
transplantation, is a good indicator of graft failure and subse-
quent graft loss. In addition, continued suppression of KICG 
«0.10 min- l by KICG-B and <0.075 minI by KICG-F) during 
the early postoperative period of 7 days was found to be 
closely associated with the severity of preservation injury, 
prolonged liver dysfunction, or septic complication, and re-
sulting longer ICU and hospital stay. Irrespective of postop-
erative days and graft quality, administration ofICG to recip-
ients, at a dose of 0.5 mg/kg, had no detrimental effect on 
graft survival and function of hepatic allografts. 
Because of its safety and negligible extrahepatic elimina-
tion, the ICG test has been used, by either bolus injection or 
continuous infusion, to medically determine the functional 
capacity of diseased livers.28 •24 In the field of general surgery, 
it has also been used to predict the outcome of patients with 
liver abnormalities before and/or after major hepatic resec-
tions. 2'.26 Recently, the application ofICG testing has gradu-
ally expanded to liver transplantation. 5-7,1l,12 While the abil-
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ity ofICG test results to predict short-term graft outcome is 
controversial when applied to donors before procurement,H.12 
this test has been reported to have some prognostic power 
when used in smaller numbers of patients after liver trans-
plantation.5 .6 This finding has been confirmed by our study. 
As a primary cutoff value for predicting graft failure, 
Lamesch et al. 5 used an ICG half-life of 12 minutes, and Jalan 
et al.6 selected an ICG clearance of200 mUmin. These figures 
correspond well to our cutoff ofKICG-B at 0.06 min 1 and K1CG-
Fat 0.04 min-I, assuming an average plasma volume of 50 
mIlkg and body weight of 70 kg. In addition, most of the 
failed grafts in the Lamesch series had an ICG half-life 
greater than 7 minutes which is equivalent to our secondary 
cutoff levels ofKrcG-B at 0.10 min-I and KrCG-F of 0.075 min-I. 
KrcG is a function of hepatic blood flow, hepatic dye clear-
ance, and plasma volume; however, hepatic blood flow is the 
major determinant of KrcG in normallivers. 27 During the im-
mediate postoperative period, plasma volume appears to 
have little influence on KICG levels, because plasma volume 
is expanded as a result of fluid and blood supplementation 
during and after surgery. Although hepatic blood flow in func-
tioning liver grafts after transplantation was reported to in-
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crease by persistent hyperdynamic circulation and hepatic 
denervation,28-3o KlCG levels on POD 1 of group I grafts, most 
of which had no to mild preservation injury (KTCG-B: 0.169 
[0.087 - 0.253], n = 26) were slightly lower than those of 
normal healthy volunteers (KICG-B: 0.187 [0.160-0.2471, n = 
20). The difference may reflect the presence of hepatocyte 
dysfunction even in well-functioning grafts caused during 
procurement, preservation, and transplantation. Although 
not investigated in this study, lower K]cG levels with group 
IIA grafts appeared to reflect decreased hepatic blood flow 
rather than hepatocyte damage because there was no correla-
tion between values of KrcG and released liver enzymes. Re-
cent experimental studies have shown that hypothermic 
preservation of the liver causes greater damage to the micro-
vasculature than to the hepatocytes.31 Using a microfil perfu-
sion technique, we have previously shown that microcircula-
tory damage is augmented after graft reperfusion causing 
stagnation, pooling, and a filling-defect in the sinusoids, as 
well as a reduction in hepatic blood flow, particularly in arte-
rial flow. 32 Studies aimed at expanding the microvasculature 
during liver preservation 33 or modulation of vasoactive sub-
stances34 were shown to improve hepatic blood flow, ICG 
elimination, and graft function after reperfusion. Further 
study on the role of hepatic blood flow in the determination 
of K]c(; levels and posttransplant graft function is needed. 
Lower K]cG levels were not only related to poor outcome 
and preservation injury, but were also associated with septic 
complications, delayed graft function, and longer ICU and 
hospital stays. However, neither K]cG levels nor liver function 
tests correlated with the incidence of graft rejection. This is 
in contrast to the observation by Howard et a1. 35 who reported 
that the incidence of rejection was higher in patients with 
"severe preservation injury" estimated by higher AST level 
TABLE 2. Correlation of KICe and Liver Function Tests With Clinical 
Outcome After 50 Orthotopic Liver Transplantations 
Univariate Multivariate Analysis 
Analysis 
Variables 
Outcome (N) Variables (POD)" (POD) P 
Overall graft loss (12) KrCG-B (1, 3, 7) KrC(;-B (1) 
KlCG-F (1, 3, 7) Highest PT .0899 
T. Bil \:1, 7) 
Highest PT .0068 
Hepatic graft loss (7) Krcu-B (1, 3, 7) KrcG-B (1) .0003 
KrcG-F (1, 3, 7) Highest PT .0815 
T. Bil (3, 7) 
Highest PT 
N onhepatic graft loss (5) 
ICU stay> 7 days (30) K[cG-B (3, 7) KrcG-F (7) .004 
KrcG-F (3, 7) 
Hospital stay >- :30 days (29) K[cc-B [1. 3,7) K'CG-F (7; <.00(11 
KrcG-F (1, 3, 7) 
Prolonged graft 
dysfunction (15) Krcc-B (7) T. Bil (7) .0001 
KICC-F (/) 
T. Bil \3,7) 
Preservation injury (20) KWG-B (1, 3, 7) KrcG-F (3) <.0001 
KrCG-F (1, 3, 71 Highest ALT .0004 
T. Bil (3, 7) 
Highest AST 
HighestAI.T 
Highest PT 
Sepsis (121 KICC-B (1, 3, 7) K[cG-B (7, .0001 
KrcG-F (1, 3, 7) 
T. Bil (3,7) 
Rejection (22) 
Abbreviations: T. Bil, total bilirubin; K[c[;-B, measurement by spectrophoto-
metric method; KrcG-F, measurement by finger-piece method. 
* Parameters that have a P value < .01. 
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FIG. 5. Correlation of Krcu-B levels with MEGX on POD 1. MEGX value 
was calculated by subtracting the O-minute value from the 30-minute value. 
Group I: patients with a functioning graft; group IIA: patients with graft loss 
caused by graft failure; and group IIB: liver-unrelated graft loss. 
after transplantation. The potent tacrolimus-based immuno-
suppression used with our patients may have concealed the 
effect of preservation injury on graft rejection. 
Along with the standard spectrophotometric analysis, a 
new optical fing:er-piece method was used in this study to 
evaluate whether the latter can simplify the ICG elimination 
test and yet provide reliable results. Although KICG-F values 
were more widely dispersed at higher levels and were consis-
tently lower at lower levels than those of KICG-B, both mea-
surements showed strong correlation. The differing behavior 
ofKrcG-F in the higher and lower range may reflect changes in 
systemic or peripheral hemodynamics that invariably occur 
after liver transplantation and accompany the use of vaso-
active agents and/or immunosuppressants. Whatever the 
reason, the fluctuation in KTCG-F appears to be insignificant 
clinically, because lower Krcc;-F values always indicated 
lesser quality of hepatic allografts in our study. More impor-
tantly, this novel method has advantages in simplicity, 
noninvasiveness, real-time presentation of test results, and 
cost-effectivenessY The optical finger-piece method also 
eliminates the need for serial blood samplings, their prepara-
tions, and actual measurements that are required for the 
standard spectrophotometric assay. In addition, the finger-
piece method may be superior to the classic ear densitome-
try36 in terms of short idling or calibration time, better base-
line stability, and better fitness. The results of this study 
warrant a large scale investigation into the suitability ofICG 
for predicting outcome not only of the grafts after operation, 
but also of the patients awaiting liver transplantation. 
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